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Abstract: 
Purpose: People with chronic kidney disease (CKD) have an increased 
prevalence of depression, anxiety, and neuropathic pain. We examined 
prevalence, incidence, indication for, and choice of antidepressants among 
patients with and without CKD.  
Methods: Using the UK Clinical Practice Research Datalink, we identified 
patients with CKD (two measurements of estimated glomerular filtration 
rate <60 mL/min/1.73m2 for ≥3 months) between April 2004 and March 
2014. We compared those with CKD to a general population cohort without 
CKD (matched on age, sex, general practice, and calendar time [index 
date]). We identified any antidepressant prescribing in the six months prior 
to index date (prevalence), the first prescription after index date among 
non-prevalent users (incidence), and recorded diagnoses (indication). We 
compared antidepressant choice between patients with and without CKD 
among patients with a diagnosis of depression.  
Results: There were 242,349 matched patients (median age 76 
http://mc.manuscriptcentral.com/pds
Pharmacoepidemiology and Drug Safety
For Review Only
[interquartile range 70-82], male 39.3%) with and without CKD. 
Prevalence of antidepressant prescribing was 16.3% and 11.9%, and 
incidence was 57.2 and 42.4/1000 person-years, in patients with and 
without CKD respectively. After adjusting for confounders, CKD remained 
associated with higher prevalence and incidence of antidepressant 
prescription. Regardless of CKD status, selective serotonin reuptake 
inhibitors were predominantly prescribed for depression or anxiety, while 
tricyclic antidepressants were prescribed for neuropathic pain or other 
reasons. Antidepressant choice was similar in depressed patients with and 
without CKD.  
Conclusions: The rate of antidepressant prescribing was nearly one and a 
half times higher among people with CKD than in the general population. 
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Key points: 
- This study examined details of antidepressant prescribing in patients with chronic kidney 
disease using a large, contemporary UK database of routine medical record data. We 
defined chronic kidney disease using serum creatinine measurements and compared 
people with and without chronic kidney disease matched for age, sex, general practice, 
and calendar time. 
- Patients with chronic kidney disease were exposed to antidepressants more frequently; 
with higher prevalence and incidence of antidepressant prescribing than the general 
population. The positive association between chronic kidney disease and increased 
frequency of antidepressant prescribing remained after adjusting for measured 
confounders such as diabetes and cardiovascular disease.  
- Among patients starting antidepressants, indication for antidepressant prescription 
(recorded diagnoses of depression, anxiety, or neuropathic pain) was similar between 
patients with and without chronic kidney disease. Antidepressant choice was also similar 
between depressed patients with and without chronic kidney disease.  
 
Name of any sponsor of the research contained in the paper, along with grant number: 
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Abstract 
Purpose: People with chronic kidney disease (CKD) have an increased prevalence of 
depression, anxiety, and neuropathic pain. We examined prevalence, incidence, indication for, 
and choice of antidepressants among patients with and without CKD.  
Methods: Using the UK Clinical Practice Research Datalink, we identified patients with 
CKD (two measurements of estimated glomerular filtration rate <60 mL/min/1.73m
2 
for ≥3 
months) between April 2004 and March 2014. We compared those with CKD to a general 
population cohort without CKD (matched on age, sex, general practice, and calendar time 
[index date]). We identified any antidepressant prescribing in the six months prior to index 
date (prevalence), the first prescription after index date among non-prevalent users 
(incidence), and recorded diagnoses (indication). We compared antidepressant choice 
between patients with and without CKD among patients with a diagnosis of depression.  
Results: There were 242,349 matched patients (median age 76 [interquartile range 70-82], 
male 39.3%) with and without CKD. Prevalence of antidepressant prescribing was 16.3% and 
11.9%, and incidence was 57.2 and 42.4/1000 person-years, in patients with and without 
CKD respectively. After adjusting for confounders, CKD remained associated with higher 
prevalence and incidence of antidepressant prescription. Regardless of CKD status, selective 
serotonin reuptake inhibitors were predominantly prescribed for depression or anxiety, while 
tricyclic antidepressants were prescribed for neuropathic pain or other reasons. 
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Antidepressant choice was similar in depressed patients with and without CKD. 
Conclusions: The rate of antidepressant prescribing was nearly one and a half times higher 
among people with CKD than in the general population. 
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Introduction 
Antidepressants are among the most commonly prescribed classes of medication in 
industrialized countries, including the US
1
 and UK.
2
 The recent increase in the prescription of 
antidepressants is dramatic, with an average 10% increase per year from 1998 to 2010.
3
 
Antidepressants can be prescribed not only for depressive symptoms but also for other 
conditions such as anxiety and neuropathic pain.
4
 In addition, off-label use of antidepressants 
is common for chronic pain, including non-neuropathic pain, and conditions where 
non-specific sedation is required.
5-7
 
 Chronic kidney disease (CKD), an impairment of kidney structure or function, is 
now recognized as a major public health problem.
8
 CKD is associated with a range of 
comorbidities including obesity, hypertension, diabetes, and cardiovascular disease.
9,10
 Level 
of kidney function, expressed as estimated glomerular filtration rate (eGFR), is closely 
associated with increased risk of death, cardiovascular events, and hospitalization.
11
  
CKD is also associated with a range of mental health problems including anxiety
12
 
and depression
13
; almost one quarter of adults with pre-dialysis CKD are depressed. These 
conditions may be due to co-existing chronic diseases such as diabetes and heart failure, 
which are also associated with depression and anxiety symptoms,
14,15
 or directly related to 
CKD. In addition, other indications for antidepressants such as chronic pain and insomnia are 
more common among patients with CKD.
16,17
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Patients with CKD are frequently excluded from clinical trials,
18,19
 and concerns 
have been recently raised about the lack of knowledge regarding how kidney function is 
related to adverse effects of antidepressants.
20,21
 Despite this, there has been no systematic 
research investigating frequency and patterns of antidepressant prescribing among patients 
with CKD. Understanding how antidepressants are actually prescribed in patients with CKD, 
compared to those without CKD, is important groundwork for the planning of future studies 
on the safety of antidepressants in this population. Therefore, we aimed to compare the 
frequency (prevalence and incidence), indications for, and choice of antidepressant 
prescription between patients with and without CKD, in the UK general population. 
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Methods 
Data sources 
The Clinical Practice Research Datalink (CPRD) is a database of routinely-recorded primary 
care electronic health record data from 7% of the UK population.
22
 The database includes the 
following data: patient demographics; diagnoses; prescriptions; laboratory test results; and 
referrals made by general practitioners (GPs). Diseases can be identified using diagnostic 
codes (Read codes) recorded in routine data. We used CPRD linked to additional data 
sources: the inpatient Hospital Episodes Statistics (HES) database to provide data on ethnicity 
(to improve data completeness)
23
; Office for National Statistics (ONS) data for mortality; and 
Index of Multiple Deprivation (IMD) data for deprivation indices. We obtained study 
approval from the institutional review board of the London School of Hygiene and Tropical 
Medicine (reference: 9196), as well as the Independent Scientific Advisory Committee, 
which oversees research involving CPRD data (Protocol 15_219R). Informed consent from 
individual patients was waived because the data are anonymous. 
 
Study population and matched cohort 
All adults (age 18 or older) alive and contributing to HES-linked CPRD anytime from 1
st
 
April 2004 to 31
st
 March 2014 were potentially eligible for inclusion. Patients were eligible 
for inclusion at the latest of: one year after practice registration,
24
 the date that the practice 
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reached CPRD quality control standards, or 1
st
 April 2004. Patients were no longer eligible 
for follow-up at the first of: renal replacement therapy (RRT) initiation, death, change of 
practice, last data collection from the practice, or 31
st
 March 2014. We excluded patients 
already receiving RRT (hemodialysis, peritoneal dialysis, and kidney transplantation) prior to 
cohort entry.  
First, we identified patients with CKD based on two consecutive measurements of 
eGFR <60ml/min/1.73m
2
 more than three months apart.
25
 Estimated GFR was calculated 
from serum creatinine values recorded in CPRD, using the Chronic Kidney Disease 
Epidemiology Collaboration equation.
26
 Patients, including those who had CKD before April 
2004, were included in the cohort on the date when they first satisfied the CKD definition (i.e. 
second eGFR <60ml/min/1.73m
2
) during eligible follow-up (index date).  
Next, as a control group, we selected at random patients without CKD from the 
general population. Because (i) CKD status largely depends on age and sex, and (ii) pattern 
of antidepressant prescription is expected to depend on general practice and calendar time, we 
matched controls to patients with CKD by age (same year of birth), sex, general practice, and 
calendar time. Each control entered the cohort on the same index date as their CKD 
counterpart. Individuals selected as controls (i.e. non-CKD patients) may be found to have 
CKD later; in this situation they were censored as a control at the time of satisfying CKD 
definition and contributed separately as an incident patient with CKD from that time point 
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forward (with their own matched control). 
 
Prevalence and incidence of antidepressant prescription 
We estimated the prevalence of existing users of antidepressants, defined as receiving an 
antidepressant prescription within six months prior to the index date. Incidence of 
antidepressant prescription was based on the first antidepressant prescription after index date, 
after exclusion of existing users.
27
 
 
Covariates 
In order to examine the independent association between CKD status and antidepressant 
prescription, we considered baseline characteristics of patients: age and sex; ethnicity; 
socio-economic status (SES); smoking status; body mass index (BMI); and common chronic 
physical illnesses that are considered to be associated with mental health conditions (diabetes 
mellitus, congestive heart failure, myocardial infarction, stroke, chronic obstructive 
pulmonary disease, rheumatoid arthritis, cancer, Parkinson’s disease, and epilepsy).
28,29
 Based 
on previous studies using UK primary care data,
30,31
 we classified patients with no record of 
ethnicity as white. SES was assigned by quintile at an individual level, using 2010 ONS 
estimates of the IMD (a composite area-level marker of deprivation).
32
 For patients with 
missing individual-level SES, we used the SES for the patient’s general practice. Smoking 
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status and BMI were assigned using the data recorded closest to the index date. We defined 
each chronic physical illnesse as present if a relevant diagnosis code of that illness was 
recorded at least once before a patient’s index date. 
 
Indication 
We identified morbidity codes for three common diagnoses suggesting indications for 
antidepressant prescription
4
: depression, anxiety, and neuropathic pain (included in 
Appendix 1). We included symptom codes as well as diagnostic codes because GPs in the 
UK commonly use symptom codes (e.g. “depressive symptoms”, “anxiousness”) rather than 
definitive diagnostic codes (e.g. “major depression”, “general anxiety disorder”).
33-35
 We 
included codes recorded by GPs any time prior to the first antidepressant prescription until 
three months later, to account for possible time lag in recording diagnosis codes in electronic 
health records.
36,37
 We categorized type of antidepressant, according to British National 
Formulary headings, into the following categories:
4
 Selective serotonin reuptake inhibitors 
(SSRIs), tricyclic antidepressants (TCAs), or other antidepressants. Monoamine oxidase 
inhibitors were grouped into other antidepressants because of a small number of prescriptions. 
For each type of antidepressant, we identified the proportion of patients with each indication 
as well as those with none of the three indications.  
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Choice of antidepressants and initial prescription dose 
There are 26 antidepressants currently available in the UK, only a few are indicated for 
anxiety and neuropathic pain, whilst all 26 are indicated for depressive conditions.
4
 Therefore, 
we restricted this analysis to patients with a recorded diagnosis of depression. We compared 
the pattern of antidepressant choice (the proportion of patients prescribed each antidepressant 
as their first incident prescription) between depressed patients with and without CKD. We 
also compared the initial dose prescribed in those with and without CKD to examine whether 
antidepressants were started at a lower dose in patients with CKD than those without. 
  
Statistical analyses 
We compared the baseline characteristics of patients with and without CKD using χ
2
 tests. We 
calculated crude prevalence and incidence rates for antidepressant prescribing. We then 
conducted a conditional logistic regression analysis (to account for matching) to investigate 
the association between CKD status and prevalence of antidepressant prescription. After 
excluding existing users of antidepressants (meaning matching was no longer maintained), 
we conducted an unconditional Poisson regression analysis to investigate the association 
between CKD status and incidence of new antidepressant prescription, adjusting for age, sex 
and financial year, and taking account clustering by general practice using robust standard 
errors. We adjusted for financial year (by including financial year as a categorical variable, i.e. 
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from 1
st
 April–31
st
 March for each year) because the frequency of antidepressant prescribing 
has been increasing year by year.
3
 We further adjusted for ethnicity, SES, smoking status, and 
BMI, and, then, in a fully adjusted model, also included chronic physical illnesses. In models 
including smoking status and BMI, we included an additional absent category for those with 
no recorded smoking status or BMI. In a subsequent sensitivity analysis we dropped all those 
with missing smoking or BMI status. All the data management and statistical analyses were 
conducted using STATA version 14 (Stata Corp, Texas).  
 
Renal function subgroup analyses 
To examine the association between severity of kidney function and antidepressant 
prescribing, we classified patients with CKD according to the level of kidney function on the 
index date into two categories: eGFR 30-59 (CKD stage 3), and <30 mL/min/1.73 m
2
 (CKD 
stage 4 and 5).
25
 In patients without CKD, we differentiated patients with and without serum 
creatinine results recorded in CPRD prior to index date, because these subgroups are 
expected to be systematically different due to testing incentives for those at risk of CKD in 
the UK Quality and Outcomes Framework.
38
 To compare the prevalence of existing users of 
antidepressants between subgroups of renal function, we used an unconditional logistic 
regression analysis, adjusting for age, sex and financial year, and taking account of clustering 
by general practice using robust standard errors. We also repeated all other principal analyses 
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(described under ‘Statistical analyses’ subheading) using renal function subgroups. 
 
Additional analyses 
Any difference in the duration of follow-up lengths between patients with and without CKD 
may affect the likelihood of starting antidepressants. Therefore, as a post hoc analysis, we 
compared the proportion of patients starting antidepressants within the first six months of 
follow-up in those with and without CKD.  
 We undertook a further analysis to investigate whether patients with CKD were more 
likely to start antidepressants for the first episode of depression in their life, or for a recurrent 
episode of depression. In CPRD, GPs routinely record a patient’s past medical history shortly 
after registration with a new practice and, therefore, a previous episode of depression would 
be recorded between CPRD registration and index date of the study (as index dates need to be 
at least one year after CPRD registration by our definition). Therefore, in patients starting 
antidepressants with a recorded diagnosis of depression, we compared the proportion of those 
with and without CKD who had: (1) their first depression diagnosis in CPRD recorded 
between CPRD registration and index date (more likely to suggest a recurrence); and (2) their 
first depression diagnosis recorded in CPRD after index date (more likely to suggest the first 
ever depression diagnosis).  
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Results 
Among 4,070,806 eligible patients (median age 39 [IQR 27-56], male 48.8%), we identified 
264,628 patients with CKD (median age 77 [IQR 71-83], male 38.7%) (Figure 1). Of those 
with CKD, 242,349 (91.6%) (median age 76 [IQR 70-82], male 39.3%) were matched with a 
control patient without CKD who had the same age, sex, and general practice on the index 
date of their CKD counterpart. Unmatched patients with CKD (n = 22,279) were older and 
more likely to be female (median age 88 [IQR 84-92], male 31.5%). Of the 242,349 matched 
control patients without CKD, 41,151 (17.0%) were subsequently found to have CKD.  
Compared to patients without CKD, patients with CKD were more likely to be 
deprived, ex-smokers and overweight (BMI ≥25 kg/m
2
) (Table 1). Chronic physical illnesses, 
except for Parkinson’s disease and epilepsy, were more common among patients with CKD.  
Prevalence of existing use of antidepressants at index date was 16.3% and 11.9% in 
patients with and without CKD, respectively (Table 2). The incidence rate of new 
antidepressant prescription was 57.2 and 42.4/1000 person-years in patients with and without 
CKD, respectively (Table 3). After adjusting for confounding, CKD remained positively 
associated with increased prevalence and incidence of antidepressant prescribing (Tables 2 
and 3). Our results were similar to those in the main analysis after excluding patients with 
missing smoking status and BMI (data not shown). 
The pattern of recorded diagnoses was broadly similar between patients with and 
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without CKD (Table 4). Regardless of CKD status, the majority of patients prescribed SSRIs 
had recorded diagnoses of depression or anxiety, while TCAs were prescribed for neuropathic 
pain or other reasons. Among patients with a recorded diagnosis of depression, the choice of 
antidepressant was similar between patients with and without CKD (Table 5). Irrespective of 
CKD status, the most commonly prescribed antidepressant was citalopram, followed by 
amitriptyline, fluoxetine, sertraline, and mirtazapine. There was no clear evidence that 
antidepressants were started at a reduced dose in patients with CKD, compared to those 
without CKD. 
When we repeated our analyses in subgroups of renal function (Appendix 2 Tables 
1-5), as the level of kidney function decreased patients tended to be older and sicker. Among 
patients without CKD, those with serum creatinine results recorded in CPRD were sicker than 
those without. Prevalence and incidence of antidepressant prescribing increased among 
people with more severe kidney function: prevalence was 16.1% and 18.3%, and incidence 
was 56.9 and 62.3/1000 person-years in patients with eGFR 30-59 and <30 mL/min/1.73m
2
, 
respectively. This trend remained after adjusting for confounders. Patterns of indication for 
and choice of antidepressant, as well as initial prescription dose, were broadly similar for 
patients with different levels of kidney function. 
In additional analyses with follow-up restricted to the first six months, the 
percentage of patients starting antidepressants was higher amongst patients with CKD (3.5%; 
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7,155/202,921) than amongst those without it (2.5%; 5,233/213,611) (P < 0.001).  
The proportion of patients starting antidepressants with their first depression 
diagnosis recorded between CPRD registration and index date was larger among patients with 
CKD (5.8%; 11,781/202,921) than those without CKD (4.0%; 8,476/213,611) (P < 0.001). 
Similarly, the proportion of patients starting antidepressants with their first depression 
diagnosis recorded in CPRD after index date was larger among patients with CKD (3.6%; 
7,295/202,921) than those without CKD (2.4%; 5,112/213,611) (P < 0.001). These results 
suggest that patients with CKD are more likely than those without CKD to start 
antidepressants both for recurrent episodes of depression, and for their first ever episode of 
depression. 
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Discussion 
Main findings 
In this large study, we found that patients with CKD were more likely than patients without 
CKD to be receiving an antidepressant, or among non-users, to start one during follow-up. 
The increase in prevalence and incidence was graded according to severity of kidney function 
and the association remained after adjusting for baseline characteristics including chronic 
physical illnesses. The pattern of indication for and choice of antidepressants, as well as 
initial prescription dose, were broadly similar between patients with and without CKD.  
 
Strengths and limitations 
We used a detailed source of routinely collected data that is representative of UK population 
demographics.
22
 In the UK, GPs manage the vast majority of non-refractory cases of mental 
health disorders,
39,40
 and even when patients see psychiatrists in secondary care, prescriptions 
are usually administered by primary care.
41
 Therefore, we expect that most antidepressant 
prescriptions are captured in CPRD. To better understand the characteristics of patients with 
CKD, we used a comparison group of patients without CKD matched on age, sex, general 
practice, and calendar time. Although previous studies suggested that the proportion of 
patients with CKD receiving antidepressants may be high as an absolute value,
42,43
 we are not 
aware of any study that has directly compared frequency and patterns of antidepressant 
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prescribing between patients with and without CKD. We defined CKD using eGFR calculated 
from serum creatinine measurement. This method is more accurate than using recorded 
diagnosis of CKD, which has low sensitivity for detecting people with CKD in UK primary 
care databases.
44
 
We must acknowledge several limitations of our study. Firstly, serum creatinine 
testing in primary care is not universal – currently it is only recommended and incentivized 
for people who are considered to be at risk for CKD.
9,38
 We may have misclassified patients 
with unmeasured CKD to the matched control cohort, which could dilute the true association 
between CKD and antidepressant prescription. However, a recent study showed that the 
prevalence of CKD identified in CPRD is similar to that estimated in a 
nationally-representative survey (Health Survey for England), suggesting that most CKD 
patients are captured in CPRD.
45
 Secondly, although we adjusted for important confounders 
that may be associated with mental health conditions,
28,29
 the observed association between 
CKD status and the prevalence/incidence of antidepressant prescribing could be influenced 
by residual confounding due to un-coded poor health status or access to talking therapies. 
Thirdly, we examined three common diagnoses associated with antidepressant use 
(depression, anxiety, and neuropathic pain). However, for patients with two or more different 
diagnoses (e.g. depression and neuropathic pain), it was not possible to determine the most 
likely indication for antidepressant prescription because diagnosis and prescription records 
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are separate in CPRD. Also, patients may have received antidepressants for other reasons, 
such as non-neuropathic pain and insomnia, but reliable identification of these conditions has 
not been established in CPRD. Finally, we demonstrated that the initial dose of antidepressant 
prescribed was similar in depressed patients with and without CKD. However, this does not 
ensure that the subsequent dose was also similar between those with and without CKD (as 
doctors may increase or decrease antidepressant dose after initial prescription, according to 
perceived effectiveness or side effects).  
 
Comparison with other studies 
Two studies conducted in the US have examined antidepressant use in patients with CKD.
42,43
 
The Chronic Renal Insufficiency Cohort study investigated the proportion of patients with 
CKD receiving an antidepressant at recruitment.
43
 Of 3,853 participants, 700 (18.2%) were 
taking antidepressants. This number is close to the prevalence of existing users of 
antidepressants in patients with CKD (16.3%) found in our study. Another US cohort study 
showed that around 30% of patients with CKD (with or without diagnosis of depression) 
were receiving antidepressants at any time during a two-year period between 2004 and 
2006.
42
 These antidepressant users appeared to include both existing and new users of 
antidepressants. Our study demonstrated the incident rate of antidepressant prescription at 
57.2/1000 person-years in patient with CKD. Together with the prevalence of existing users 
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(16.3%), the cumulative effect of this was consistent with over 30% of CKD patients exposed 
to antidepressants during follow-up. Neither US study included a comparison group of 
patients without CKD in order to compare prescribing in CKD patients to that in the general 
population. Indication and choice of antidepressants were also not examined.  
 
Explanation of findings and implication for future studies 
Patients with mild CKD generally do not have related physical symptoms. However, a 
previous study has suggested that negative perception of CKD is associated with depression 
and lower quality of life, even in the early stages of CKD.
46
 Patients with more advanced 
CKD (eGFR <30 mL/min/1.73m
2
) tend to have symptoms including fatigue, nausea, sleep 
disturbances, itching, and peripheral neuropathy, any of which could influence quality of life 
and mental health. This is in line with our finding that patients with advanced CKD were 
more likely to be prescribed antidepressants, even without a specifically coded diagnosis of 
depression and anxiety.  
 While most SSRIs were associated with a coded diagnosis of depression or anxiety, 
more than half of patients starting TCAs (mostly amitriptyline) did not have any recorded 
diagnoses of depression, anxiety or neuropathic pain. Amitriptyline may have been 
predominantly prescribed as an off-label indication for non-psychiatric conditions such as 
chronic pain and insomnia.
5-7
 When restricted to patients with a coded diagnosis of 
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depression, SSRIs accounted for the majority of antidepressant prescribing, which is in 
keeping with current guidelines for management of depression.
39
 Patterns of antidepressant 
choice did not differ substantially according to CKD status or level of kidney function. This 
is probably because to date there is no evidence of greater efficacy or safety concerns for 
specific antidepressants among patients with CKD.
20,21
  
Increased adverse events as renal function declines is an important concern. For 
example, amitriptyline clearance is reduced in patients with decreased kidney function.
47
 As a 
result, amitriptyline may accumulate, causing serious adverse outcomes through 
neurotoxicity
48
 and cardiotoxicity.
49
 Another example is the potential amplification of 
bleeding risk both with use of SSRIs and with decreased kidney function itself.
50
 Finally, the 
results of our analyses stratified by severity of renal function demonstrate that many patients 
are prescribed antidepressants at levels of renal function below those where cessation is 
recommended by manufacturers (e.g. eGFR <30 mL/min/1.73m
2
). According to the British 
National Formulary,
4
 escitalopram, paroxetine, sertraline, imipramine, lofepramine, 
trazodone, duloxetine, mirtazapine, and venlafaxine should be used with caution or avoided 
in those with reduced renal function, but our real-world data suggest that these drugs are 
prescribed similarly in patients with moderately or severely decreased kidney function, 
compared to those with normal kidney function. Better evidence regarding the potential 
adverse effects of these drugs for patients with decreased kidney function is needed. 
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Conclusions 
This study using a large UK database suggests that patients with CKD are more likely to be 
prescribed antidepressants than the general population, whilst prescribing patterns did not 
appear to be influenced by kidney function. These real-world data emphasize the need for 
research investigating the potential adverse effects of antidepressant therapy in people with 
decreased kidney function. 
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Figure legends 
Figure 1. Flow chart for the selection of matched patients with and without chronic kidney 
disease 
CKD = chronic kidney disease, CPRD = clinical practice research datalink, HES = hospital 
episode statistics, RRT = renal replacement therapy. 
*Matched cohort: randomly selected individuals without chronic kidney disease matched for 
age, sex, general practice, and calendar time. 
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Table 1. Baseline characteristics of matched patients with and without chronic kidney disease. 
 
Patients without CKD 
N = 242,349 
Patients with CKD 
N = 242,349 P value 
 n (%) n (%) 
Age (years):   1.000 
 <55 6,845 (2.8) 6,845 (2.8)  
 55-64 23,556 (9.7) 23,556 (9.7)  
 65-74 71,112 (29.3) 71,112 (29.3)  
 75-84 102,594 (42.3) 102,594 (42.3)  
 ≥85 38,242 (15.8) 38,242 (15.8)  
Sex (male): 95,318 (39.3) 95,318 (39.3) 1.000 
Ethnicity:    
 White/not-recorded* 238,533 (98.4) 238,138 (98.3) <0.001 
 South Asian  1,796 (0.7) 2,317 (1.0)  
 Black 1,156 (0.5) 1,060 (0.4)  
 Other ethnicity 864 (0.4) 834 (0.3)  
Socio-economic status**:    
  1 (least deprived) 56,800 (23.4) 53,034 (21.9) <0.001 
  2 61,647 (25.4) 60,501 (25.0)  
  3 50,466 (20.8) 50,709 (20.9)  
  4 42,221 (17.4) 44,692 (18.4)  
  5 (most deprived) 31,215 (12.9) 33,413 (13.8)  
Smoking status:   <0.001 
  Non-smoker 92,363 (38.1) 80,721 (33.3)  
  Ex-smoker 107,737 (44.5) 131,510 (54.3)  
  Current-smoker 36,338 (15.0) 29,243 (12.1)  
  Missing 5,911 (2.4) 875 (0.4)  
Body mass index (kg/m
2
):   <0.001 
  <18.5 6,638 (2.7) 4,562 (1.9)  
18.5 - 25 85,473 (35.3) 70,102 (28.9)  
  ≥25 80,458 (33.2) 88,083 (36.4)  
  ≥30 40,326 (16.6) 63,183 (26.1)  
  Missing 29,454 (12.2) 16,419 (6.8)  
Chronic physical illnesses:    
  Diabetes mellitus 24,292 (10.0) 52,802 (21.8) <0.001 
  Congestive heart failure 7,581 (3.1) 23,774 (9.8) <0.001 
  Myocardial infarction 11,459 (4.7) 25,746 (10.6) <0.001 
  Stroke 12,243 (5.1) 19,982 (8.3) <0.001 
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  Chronic obstructive pulmonary disease 14,996 (6.2) 18,229 (7.5) <0.001 
  Rheumatoid arthritis 4,270 (1.8) 6,031 (2.5) <0.001 
  Cancer 47,431 (19.6) 54,450 (22.5) <0.001 
  Parkinson’s disease 2,691 (1.1) 2,293 (1.0) <0.001 
  Epilepsy 3,972 (1.6) 3,682 (1.5) 0.001 
CKD = chronic kidney disease. 
* White/not-recorded: 136,119 (56.2%) and 140,784 (58.1%) patients with and without CKD respectively, had no 
recorded ethnicity.  
** Socio-economic status: 259 (0.1%) and 272 (0.1%) patients with and without CKD respectively, did not have 
individual-level data, we therefore used the socio-economic status of their general practice. . 
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Table 2. Prevalence of antidepressant prescription by chronic kidney disease status. 
 
 No. of patients receiving 
antidepressants in the past 6 months 
Prevalence  
% (95% CI) 
Adjusted odds ratio (95% CI) 
Model 1* Model 2** Model 3*** 
Patients without CKD (N = 242,349) 28,738 11.9 (11.7 – 12.0) 1 (Reference) 1 (Reference) 1 (Reference) 
Patients with CKD (N = 242,349) 39,428 16.3 (16.1 – 16.4) 1.46 (1.43 – 1.48) 1.43 (1.41 – 1.46) 1.35 (1.32 – 1.37) 
CI = confidence interval, CKD = chronic kidney disease. 
*Model 1: Accounted for the matched nature of the groups (age, sex, general practice, and calendar time) in conditional logistic regression analysis. 
**Model 2: Model 1 + adjusted by ethnicity, socio-economic status, smoking status, and body mass index. 
***Model 3: Model 2 + adjusted by chronic physical illnesses. 
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Table 3. Incidence of new antidepressant prescription by chronic kidney disease status. 
 
 Total follow-up 
length 
(person-years) 
No. of patients 
starting 
antidepressants 
Incidence rate  
(/1000 person-years)  
(95%CI) 
Adjusted rate ratio (95%CI) 
Model 1* Model 2** Model 3*** 
Patients without CKD (N = 213,611) 774,660 32,846 42.4 (41.9 – 42.9) 1 (Reference) 1 (Reference) 1 (Reference) 
Patients with CKD (N = 202,921) 794,150 45,394 57.2 (56.6 – 57.7) 1.35 (1.33 – 1.37) 1.30 (1.28 – 1.32) 1.25 (1.23 – 1.26) 
CI = confidence interval, CKD = chronic kidney disease, IQR = interquartile range.  
*Model 1: Adjusted by age, sex and financial year, and taking account of clustering by general practice with robust standard errors using unconditional Poisson regression 
analysis. 
**Model 2: Model 1 + adjusted by ethnicity, socio-economic status, smoking status and body mass index. 
***Model 3: Model 2 + adjusted by chronic physical illnesses. 
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Table 4. Recorded diagnoses for patients prescribed antidepressants stratified by chronic kidney disease status and type of antidepressant.  
 
 
 Patients without CKD (N = 32,846) Patients with CKD (N = 45,394) 
 
 
SSRI 
N = 12,924 
TCA 
N = 17,672 
Others 
N = 2,250 
SSRI 
N = 17,992 
TCA 
N = 24,262 
Others 
N = 3,140 
Depression, n (%)* 8,123 (62.9) 4,430 (25.1) 1,035 (46.0) 11,363 (63.2) 6,257 (25.8) 1,456 (46.4) 
Anxiety, n (%)* 4,843 (37.5) 3,902 (22.1) 708 (31.5) 6,131 (34.1) 5,055 (20.8) 935 (29.8) 
Neuropathic pain, n (%)* 625 (4.8) 2,536 (14.4) 152 (6.8) 997 (5.5) 3,491 (14.4) 209 (6.7) 
None of the above, n (%) 3,188 (24.7) 9,699 (54.9) 894 (39.7) 4,683 (26.0) 13,259 (54.7) 1,256 (40.0) 
CKD = chronic kidney disease, SSRI = selective serotonin reuptake inhibitor, TCA = tricyclic antidepressants. 
*Percentages are column percentages. Each patient may have one or more recorded diagnosis.  
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Table 5. Choice of antidepressants and initial prescription dose for patients with diagnosed depression by chronic 
kidney disease status.  
 
Patients without CKD 
N = 13,588 
Patients with CKD  
N = 19,076 
 n (%)* 
Median initial dose 
(mg/day) [IQR]  
n (%)* 
Median initial dose 
(mg/day) [IQR] 
Selective serotonin reuptake inhibitors     
Citalopram 4,934 (36.3) 10 [10 – 20] 7,070 (37.1) 10 [10 – 20] 
Escitalopram 353 (2.6) 5 [5 – 10] 429 (2.3) 5 [5 – 10] 
Fluoxetine 1,651 (12.2) 20 [20 – 20] 2,270 (11.9) 20 [20 – 20] 
Fluvoxamine <5 (<0.1) n/a <5 (<0.1) n/a 
Paroxetine 132 (1.0) 20 [20 – 20] 144 (0.8) 20 [20 – 20] 
Sertraline 1,053 (7.8) 50 [50 – 50] 1,449 (7.6) 50 [50 – 50] 
Tricyclic and related antidepressants     
Amitriptyline 3,506 (25.8) 10 [10 – 20] 5,024 (26.3) 10 [10 – 15] 
Clomipramine 26 (0.2) 25 [10 – 37.5] 27 (0.1) 20 [10 – 37.5] 
Dosulepin 407 (3.0) 37.5 [25 – 75] 512 (2.7) 37.5 [25 – 75] 
Doxepin 19 (0.1) 25 [25 – 37.5] 24 (0.1) 25 [20 – 30] 
Imipramine 30 (0.2) 25 [10 – 30] 45 (0.2) 25 [10 – 30] 
Lofepramine 113 (0.8) 70 [70 – 140] 186 (1.0) 70 [70 – 140] 
Nortriptyline 94 (0.7) 15 [10 – 15] 158 (0.8) 10 [10 – 15] 
Trimipramine 15 (0.1) 25 [10 – 37.5] 26 (0.1) 25 [20 – 50] 
Mianserin 7 (0.1) 30 [30 – 30] 5 (<0.1) 30 [30 – 30] 
Trazodone 213 (1.6) 50 [50 – 100] 250 (1.3) 50 [50 – 75] 
Monoamine oxidase inhibitors** <5 (<0.1) n/a <5 (<0.1) n/a 
Other antidepressants:     
Agomelatine <5 (<0.1) n/a <5 (<0.1) n/a 
Duloxetine  98 (0.7) 40 [30 – 60] 169 (0.9) 40 [30 – 60] 
Flupentixol 63 (0.5) 1 [0.5 – 1] 88 (0.5) 1 [0.5 – 1] 
Mirtazapine 758 (5.6) 15 [15 – 15] 1,045 (5.5) 15 [15 – 15] 
Reboxetine <5 (<0.1) n/a <5 (<0.1) n/a 
Venlafaxine 85 (0.6) 75 [75 – 75] 97 (0.5) 75 [75 – 75] 
Two or more different antidepressants  27 (0.2) n/a 53 (0.3) n/a 
CKD = chronic kidney disease, IQR = interquartile range. 
*Cell counts less than five have been suppressed to preserve patient privacy.  
**Phenelzine, isocarboxazid, tranylcypromine, and moclobemide are combined due to small sample sizes. 
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All adults without RRT
N = 4,070,806
All adults in HES-linked CPRD between 1st April 2004 and 31st March 2014
N = 4,073,639
People with CKD
N = 264,628
Matched controls* 
N = 242,349
People with CKD and a matched control available 
N = 242,349
Patients already on RRT : N = 2833
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Appendix 1. List of diagnosis codes indicative of depression, anxiety, and neuropathic pain in 
Clinical Practice Research Datalink. 
Read code Medcode* Read term 
Depression: 
E2B..00 324 Depressive disorder NEC 
Eu32z11 543 [X]Depression NOS 
E112.14 595 Endogenous depression 
E200300 655 Anxiety with depression 
E135.00 1055 Agitated depression 
E204.00 1131 Neurotic depression reactive type 
Eu31.11 1531 [X]Manic-depressive illness 
E290.00 1533 Brief depressive reaction 
2257.00 1908 O/E - depressed 
1B17.00 1996 Depressed 
1B1N.00 2147 Poor self esteem 
E11..12 2560 Depressive psychoses 
E204.11 2639 Postnatal depression 
1465.00 2716 H/O: depression 
62T1.00 2923 Puerperal depression 
1B17.12 2930 C/O - feeling unhappy 
Eu32z00 2970 [X]Depressive episode, unspecified 
E2B0.00 2972 Postviral depression 
Eu32z12 3291 [X]Depressive disorder NOS 
Eu33.00 3292 [X]Recurrent depressive disorder 
E2B1.00 4323 Chronic depression 
Eu32.00 4639 [X]Depressive episode 
E115.00 4677 Bipolar affective disorder, currently depressed 
Eu31500 4732 [X]Bipolar affect dis cur epi severe depres with psyc symp 
1B17.11 4824 C/O - feeling depressed 
Eu53012 4979 [X]Postpartum depression NOS 
E112.11 5879 Agitated depression 
Eu32z14 5987 [X] Reactive depression NOS 
E113700 6482 Recurrent depression 
E112.12 6546 Endogenous depression first episode 
Eu32y00 6854 [X]Other depressive episodes 
E113.11 6932 Endogenous depression - recurrent 
E112.13 6950 Endogenous depression first episode 
E112z00 7011 Single major depressive episode NOS 
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1BJ..00 7412 Loss of confidence 
Eu32.13 7604 [X]Single episode of reactive depression 
Eu34113 7737 [X]Neurotic depression 
Eu41211 7749 [X]Mild anxiety depression 
Eu34100 7953 [X]Dysthymia 
E130.00 8478 Reactive depressive psychosis 
Eu34111 8584 [X]Depressive neurosis 
Eu33.15 8826 [X]SAD - Seasonal affective disorder 
Eu33.11 8851 [X]Recurrent episodes of depressive reaction 
Eu33.13 8902 [X]Recurrent episodes of reactive depression 
1BT..11 8928 Low mood 
Eu32.11 9055 [X]Single episode of depressive reaction 
E11z200 9183 Masked depression 
Eu32100 9211 [X]Moderate depressive episode 
Eu32200 9667 [X]Severe depressive episode without psychotic symptoms 
1B1U.00 9796 Symptoms of depression 
1BT..00 10015 Depressed mood 
Eu34112 10290 [X]Depressive personality disorder 
1B1U.11 10438 Depressive symptoms 
E211200 10455 Depressive personality disorder 
E112.00 10610 Single major depressive episode 
Eu32400 10667 [X]Mild depression 
Eu32y11 10720 [X]Atypical depression 
E118.00 10825 Seasonal affective disorder 
Eu33212 11252 [X]Major depression, recurrent without psychotic symptoms 
Eu33211 11329 [X]Endogenous depression without psychotic symptoms 
E11y000 11596 Unspecified manic-depressive psychoses 
Eu32000 11717 [X]Mild depressive episode 
Eu41200 11913 [X]Mixed anxiety and depressive disorder 
Eu32300 12099 [X]Severe depressive episode with psychotic symptoms 
E115.11 12831 Manic-depressive - now depressed 
Eu53011 13307 [X]Postnatal depression NOS 
E113200 14709 Recurrent major depressive episodes, moderate 
E113.00 15099 Recurrent major depressive episode 
E112200 15155 Single major depressive episode, moderate 
E112300 15219 Single major depressive episode, severe, without psychosis 
Eu34114 15220 [X]Persistant anxiety depression 
E115000 15923 Bipolar affective disorder, currently depressed, unspecified 
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E112100 16506 Single major depressive episode, mild 
Eu31300 16562 [X]Bipolar affect disorder cur epi mild or moderate depressn 
E291.00 16632 Prolonged depressive reaction 
Eu33315 16861 [X]Recurrent severe episodes of psychotic depression 
E130.11 17770 Psychotic reactive depression 
Eu32.12 18510 [X]Single episode of psychogenic depression 
Eu3y111 19054 [X]Recurrent brief depressive episodes 
Eu33.12 19696 [X]Recurrent episodes of psychogenic depression 
Eu20400 20785 [X]Post-schizophrenic depression 
E002100 21887 Senile dementia with depression 
ZV11112 22080 [V]Personal history of manic-depressive psychosis 
Eu33400 22116 [X]Recurrent depressive disorder, currently in remission 
Eu32212 22806 [X]Single episode major depression w'out psychotic symptoms 
Eu31400 23713 [X]Bipol aff disord, curr epis sev depress, no psychot symp 
Eu33311 23731 [X]Endogenous depression with psychotic symptoms 
ZV11111 23963 [V]Personal history of manic-depressive psychosis 
Eu32313 24112 [X]Single episode of psychotic depression 
Eu32311 24117 [X]Single episode of major depression and psychotic symptoms 
E113400 24171 Recurrent major depressive episodes, severe, with psychosis 
1BQ..00 25435 Loss of capacity for enjoyment 
E113z00 25563 Recurrent major depressive episode NOS 
E113300 25697 Recurrent major depressive episodes, severe, no psychosis 
1BT..12 26028 Sad mood 
E11y200 27491 Atypical depressive disorder 
E001300 27677 Presenile dementia with depression 
Eu02z16 27759 [X] Senile dementia, depressed or paranoid type 
E115200 27890 Bipolar affective disorder, currently depressed, moderate 
Eu32z13 28248 [X]Prolonged single episode of reactive depression 
Eu33312 28677 [X]Manic-depress psychosis,depressed type+psychotic symptoms 
Eu33.14 28756 [X]Seasonal depressive disorder 
Eu32314 28863 [X]Single episode of reactive depressive psychosis 
E113100 29342 Recurrent major depressive episodes, mild 
Eu33213 29451 [X]Manic-depress psychosis,depressd,no psychotic symptoms 
Eu33100 29520 [X]Recurrent depressive disorder, current episode moderate 
R007z13 29527 [D]Postoperative depression 
Eu33000 29784 [X]Recurrent depressive disorder, current episode mild 
Eu3y011 30688 [X]Mixed affective episode 
1BP..00 30740 Loss of interest 
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Eu33314 31757 [X]Recurr severe episodes/psychogenic depressive psychosis 
E112400 32159 Single major depressive episode, severe, with psychosis 
Eu33313 32941 [X]Recurr severe episodes/major depression+psychotic symptom 
Eu33200 33469 [X]Recurr depress disorder cur epi severe without psyc sympt 
Eu31z00 33751 [X]Bipolar affective disorder, unspecified 
E112000 34390 Single major depressive episode, unspecified 
E115300 35607 Bipolar affect disord, now depressed, severe, no psychosis 
E113000 35671 Recurrent major depressive episodes, unspecified 
E115100 35734 Bipolar affective disorder, currently depressed, mild 
E290z00 36246 Brief depressive reaction NOS 
Eu33z11 36616 [X]Monopolar depression NOS 
E115z00 37296 Bipolar affective disorder, currently depressed, NOS 
Eu33316 37764 [X]Recurrent severe episodes/reactive depressive psychosis 
E002z00 41089 Senile dementia with depressive or paranoid features NOS 
Eu32211 41989 [X]Single episode agitated depressn w'out psychotic symptoms 
E004300 43292 Arteriosclerotic dementia with depression 
E112500 43324 Single major depressive episode, partial or unspec remission 
Eu33z00 44300 [X]Recurrent depressive disorder, unspecified 
E002.00 44674 Senile dementia with depressive or paranoid features 
Eu31600 44693 [X]Bipolar affective disorder, current episode mixed 
Eu33300 47009 [X]Recurrent depress disorder cur epi severe with psyc symp 
Eu33y00 47731 [X]Other recurrent depressive disorders 
Eu32312 52678 [X]Single episode of psychogenic depressive psychosis 
1BU..00 53148 Loss of hope for the future 
Eu31y00 53840 [X]Other bipolar affective disorders 
E113600 55384 Recurrent major depressive episodes, in full remission 
E113500 56273 Recurrent major depressive episodes,partial/unspec remission 
Eu32y12 56609 [X]Single episode of masked depression NOS 
E115600 57465 Bipolar affective disorder, now depressed, in full remission 
Eu32213 59386 [X]Single episode vital depression w'out psychotic symptoms 
1BP0.00 59869 Loss of interest in previously enjoyable activity 
E11y.00 60178 Other and unspecified manic-depressive psychoses 
E115400 63701 Bipolar affect disord, now depressed, severe with psychosis 
E115500 72026 Bipolar affect disord, now depressed, part/unspec remission 
Eu31y11 73924 [X]Bipolar II disorder 
Eu33214 73991 [X]Vital depression, recurrent without psychotic symptoms 
Eu32600 98252 [X]Major depression, moderately severe 
Eu32500 98346 [X]Major depression, mild 
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Eu32700 98414 [X]Major depression, severe without psychotic symptoms 
Eu32800 98417 [X]Major depression, severe with psychotic symptoms 
Anxiety: 
1B13.00 131 Anxiousness 
E200111 462 Panic attack 
1B12.12 514 Tension - nervous 
E200.00 636 Anxiety states 
E200300 655 Anxiety with depression 
E20z.11 791 Nervous breakdown 
Eu41111 962 [X]Anxiety neurosis 
E205.11 1582 Nervous exhaustion 
E200400 1758 Chronic anxiety 
R2y2.00 2509 [D]Nervousness 
1BK..00 2524 Worried 
E202100 3076 Agoraphobia with panic attacks 
1B1..00 3328 General nervous symptoms 
E200100 4069 Panic disorder 
Eu41012 4081 [X]Panic state 
E200z00 4534 Anxiety state NOS 
E200500 4634 Recurrent anxiety 
E200200 4659 Generalised anxiety disorder 
Eu41.00 5385 [X]Other anxiety disorders 
1B13.11 5902 Anxiousness - symptom 
E292000 6221 Separation anxiety disorder 
Eu41011 6408 [X]Panic attack 
E200000 6939 Anxiety state unspecified 
Eu41211 7749 [X]Mild anxiety depression 
Z4L1.00 7999 Anxiety counselling 
Eu41000 8205 [X]Panic disorder [episodic paroxysmal anxiety] 
Eu60600 8424 [X]Anxious [avoidant] personality disorder 
2259.00 8725 O/E - nervous 
Eu41100 10344 [X]Generalized anxiety disorder 
E202D00 10390 Fear of death 
R2y2.12 10723 [D]Nervous tension 
1B1V.00 11890 C/O - panic attack 
Eu41200 11913 [X]Mixed anxiety and depressive disorder 
E280.00 11940 Acute panic state due to acute stress reaction 
E202200 12838 Agoraphobia without mention of panic attacks 
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2258.00 13124 O/E - anxious 
Eu40012 14890 [X]Panic disorder with agoraphobia 
Eu40011 16729 [X]Agoraphobia without history of panic disorder 
Eu51511 17687 [X]Dream anxiety disorder 
225J.00 19000 O/E - panic attack 
1B1Z.00 20089 General nervous symptom NOS 
1B1H.12 20163 Apprehension 
Eu41z00 23838 [X]Anxiety disorder, unspecified 
Eu41y00 24066 [X]Other specified anxiety disorders 
Eu41z11 25638 [X]Anxiety NOS 
225K.00 26331 O/E - fearful mood 
Eu41y11 28167 [X]Anxiety hysteria 
Z4I7200 28381 Alleviating anxiety 
8HHp.00 28925 Referral for guided self-help for anxiety 
1B12.00 29608 'Nerves' - nervousness 
Eu40z00 34064 [X]Phobic anxiety disorder, unspecified 
Eu41112 35825 [X]Anxiety reaction 
2255.00 38155 O/E - afraid 
1B1P000 40431 Cries easily 
Eu41300 44321 [X]Other mixed anxi ty disorders 
Eu41113 50191 [X]Anxiety state 
E292400 56924 Adjustment reaction with anxious mood 
1B13.12 93401 Anxious 
16ZB100 101422 Feeling low or worried 
Neuropathic pain: 
F262500 321 Periodic migrainous neuralgia 
F301.00 1541 Other specified trigeminal neuralgia 
A531.11 1598 Post-herpetic neuralgia 
N242000 2284 Neuralgia unspecified 
F301z00 6581 Trigeminal neuralgia NOS 
F356100 6884 Morton's neuralgia 
F300.00 7584 Post-herpetic trigeminal neuralgia 
A531511 10223 Postherpetic neuralgia 
A531200 11498 Postherpetic trigeminal neuralgia 
N242300 11544 Neuropathic pain 
1475.00 16481 H/O: trigeminal neuralgia 
F321.00 16932 Glossopharyngeal neuralgia 
A531500 17180 Postzoster neuralgia 
Page 48 of 67
http://mc.manuscriptcentral.com/pds
Pharmacoepidemiology and Drug Safety
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
*There is a one-to-one correspondence between Medcode and Read code in Clinical Practice 
Research Datalink. 
 
N242z00 23839 Neuralgia, neuritis or radiculitis NOS 
F262100 33362 Horton's (histamine) neuralgia 
F372100 35785 Chronic painful diabetic neuropathy 
F372000 48078 Acute painful diabetic neuropathy 
N242.00 54992 Neuralgia, neuritis and radiculitis unspecified 
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Appendix 2. Subgroup analyses according to level of kidney function (among patients with CKD) and creatinine measurement (among patients without CKD). 
Table 1. Baseline characteristics. 
 Patients without CKD (N = 242,349) Patients with CKD (N = 242,349) 
P value 
 
without creatinine 
measurement in CPRD  
N = 62,971 
with creatinine 
measurement in CPRD 
N = 179,378 
with eGFR 30-59 
mL/min/1.73m
2 
at baseline
 
N = 228,055 
with eGFR <30  
mL/min/1.73m
2 
at baseline
 
N = 14,294 
n (%) n (%) n (%) n (%) 
Age (years):     <0.001 
 <55 3,279 (5.2) 3,566 (2.0) 6,022 (2.6) 823 (5.8)  
 55-64 7,693 (12.2) 15,863 (8.8) 22,531 (9.9) 1,025 (7.2)  
 65-74 17,450 (27.7) 53,662 (29.9) 68,494 (30.0) 2,618 (18.3)  
 75-84 23,536 (37.4) 79,058 (44.1) 96,868 (42.5) 5,726 (40.1)  
 ≥85 11,013 (17.5) 27,229 (15.2) 34,140 (15.0) 4,102 (28.7)  
Sex (male): 23,015 (36.6) 72,303 (40.3) 89,289 (39.2) 6,029 (42.2) <0.001 
Ethnicity:     <0.001 
 White/not-recorded 62,319 (99.0) 176,214 (98.2) 224,211 (98.3) 13,927 (97.3)  
 South Asian  302 (0.5) 1,494 (0.8) 2,141 (0.9) 176 (1.2)  
 Black 146 (0.2) 1,010 (0.6) 932 (0.4) 128 (0.9)  
 Other ethnicity 204 (0.3) 660 (0.4) 771 (0.3) 63 (0.4)  
Socio-economic status:     <0.001 
  1 (least deprived) 14,724 (23.4) 42,076 (23.5) 50,295 (22.1) 2,739 (19.2)  
  2 15,603 (24.8) 46,044 (25.7) 57,190 (25.1) 3,311 (23.2)  
  3 12,950 (20.6) 37,516 (20.9) 47,616 (20.9) 3,093 (21.6)  
  4 11,222 (17.8) 30,999 (17.3) 41,829 (18.3) 2,863 (20.0)  
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  5 (most deprived) 8,472 (13.5) 22,743 (12.7) 31,125 (13.7) 2,288 (16.0)  
Smoking status:     <0.001 
  Non-smoker 27,736 (44.1) 64,627 (36.0) 75,701 (33.2) 5,020 (35.1)  
  Ex-smoker 18,549 (29.5) 89,188 (49.7) 124,290 (54.5) 7,220 (50.5)  
  Current-smoker 11,791 (18.7) 24,547 (13.7) 27,374 (12.0) 1,869 (13.1)  
  Missing 4,895 (7.8) 1,016 (0.6) 690 (0.3) 185 (1.3)  
Body mass index:     <0.001 
  <18.5 1,628 (2.6) 5,010 (2.8) 4,189 (1.8) 373 (2.6)  
18.5 - 25 21,981 (34.9) 63,492 (35.4) 65,841 (28.9) 4,261 (29.8)  
  ≥25 17,526 (27.8) 62,932 (35.1) 83,733 (36.7) 4,350 (30.4)  
  ≥30 6,829 (10.8) 33,497 (18.7) 59,910 (26.3) 3,273 (22.9)  
  Missing 15,007 (23.8) 14,447 (8.1) 14,382 (6.3) 2,037 (14.3)  
Chronic physical illnesses:      
  Diabetes mellitus 669 (1.1) 23,623 (13.2) 49,017 (21.5) 3,785 (26.5) <0.001 
  Congestive heart failure 824 (1.3) 6,757 (3.8) 20,723 (9.1) 3,051 (21.3) <0.001 
  Myocardial infarction 783 (1.2) 10,676 (6.0) 23,664 (10.4) 2,082 (14.6) <0.001 
  Stroke 1,507 (2.4) 10,736 (6.0) 18,330 (8.0) 1,652 (11.6) <0.001 
  Chronic obstructive pulmonary disease 2,312 (3.7) 12,684 (7.1) 17,006 (7.5) 1,223 (8.6) <0.001 
  Rheumatoid arthritis 527 (0.8) 3,743 (2.1) 5,674 (2.5) 357 (2.5) <0.001 
  Cancer 8,593 (13.7) 38,838 (21.7) 50,799 (22.3) 3,651 (25.5) <0.001 
  Parkinson’s disease 500 (0.8) 2,191 (1.2) 2,143 (0.9) 150 (1.1) <0.001 
  Epilepsy 670 (1.1) 3,302 (1.8) 3,450 (1.5) 232 (1.6) <0.001 
CKD = chronic kidney function, eGFR = estimated glomerular filtration rate. 
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Table 2. Prevalence of antidepressant prescription. 
 
 No. of patients receiving 
antidepressants in the 
past 6 months 
Prevalence,  
% (95% CI) 
Adjusted odds ratio (95% CI) 
Model 1* Model 2** Model 3*** 
Non-CKD patients without creatinine measurement in CPRD (N = 62,971) 4,515 7.2 (7.0 – 7.4) 0.49 (0.47 – 0.51) 0.48 (0.46 – 0.50) 0.52 (0.49 – 0.54) 
Non-CKD patients with creatinine measurement in CPRD (N = 179,378) 24,223 13.5 (13.3 – 13.7) 1 (Reference) 1 (Reference) 1 (Reference) 
CKD patients with eGFR 30-59 mL/min/1.73m
2
 at baseline (N = 228,055) 36,815 16.1 (16.0 – 16.3) 1.24 (1.22 – 1.27) 1.23 (1.21 – 1.26) 1.19 (1.16 – 1.21) 
CKD patients with eGFR <30 mL/min/1.73m2 at baseline (N = 14,294) 2,613 18.3 (17.6 – 18.9) 1.35 (1.26 – 1.44) 1.31 (1.23 – 1.41) 1.20 (1.12 – 1.29) 
CI = confidence interval, CKD = chronic kidney disease, eGFR = estimated glomerular filtration rate. 
*Model 1: Adjusted by age, sex and financial year, and taking account of clustering by general practices with robust standard errors using unconditional logistic regression analysis. 
**Model 2: Model 1 + adjusted by ethnicity, socio-economic status, smoking status and body mass index. 
***Model 3: Model 2 + adjusted by chronic physical illnesses. 
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Table 3. Incidence of new antidepressant prescription.  
 
 Total follow-up 
length  
(person-years) 
No. of patients 
starting 
antidepressants  
Incidence rate  
(/1000 person-years)  
(95%CI) 
Adjusted rate ratio (95%CI) 
Model 1** Model 2*** Model 3*** 
Non-CKD patients without creatinine measurement in CPRD (N = 58,456) 258,474 7,076 27.4 (26.7 – 28.0) 0.55 (0.53 – 0.56) 0.58 (0.56 – 0.59) 0.60 (0.59 – 0.62) 
Non-CKD patients with creatinine measurement in CPRD (N = 155,155) 516,186 25,770 49.9 (49.3 – 50.5) 1 (Reference) 1 (Reference) 1 (Reference) 
CKD patients with eGFR 30-59 mL/min/1.73m2 (N = 191,240) 762,310 43,410 56.9 (56.4 – 57.5) 1.14 (1.12 – 1.16) 1.13 (1.11 – 1.15) 1.10 (1.09 – 1.12) 
CKD patients with eGFR <30 mL/min/1.73m2 (N = 11,681) 31,839 1,984 62.3 (59.6 – 65.1) 1.24 (1.18 – 1.30) 1.23 (1.17 – 1.28) 1.16 (1.11 – 1.22) 
CI = confidence interval, CKD = chronic kidney disease, eGFR = estimated glomerular filtration rate, IQR = interquartile range.  
*Model 1: Adjusted by age, sex and financial year, and taking account of clustering by general practices with robust standard errors using unconditional Poisson regression analysis. 
**Model 2: Model 1 + adjusted by ethnicity, socio-economic status, smoking status and body mass index. 
***Model 3: Model 2 + adjusted by chronic physical illnesses. 
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Table 4. Recorded diagnoses for patients prescribed antidepressants stratified by type of antidepressant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patients without CKD (N = 32,846) 
without creatinine measurement in CPRD 
(N = 7,076) 
with creatinine measurement in CPRD 
(N = 25,770) 
SSRI 
N = 2,984 
TCA 
N = 3,591 
Others 
N = 501 
SSRI 
N = 9,940 
TCA 
N = 14,081 
Others 
N = 1,749 
Depression, n (%)* 1,741 (58.3) 759 (21.1) 197 (39.3) 6,382 (64.2) 3,671 (26.1) 838 (47.9) 
Anxiety, n (%)* 1,030 (34.5) 646 (18.0) 133 (26.6) 3,813 (38.4) 3,256 (23.1) 575 (32.9) 
Neuropathic pain, n (%)* 76 (2.6) 478 (13.3) 19 (3.8) 549 (5.5) 2,058 (14.6) 133 (7.6) 
None of the above, n (%) 850 (28.5) 2,149 (59.8) 244 (48.7) 2,338 (23.5) 7,550 (53.6) 650 (37.2) 
 
 
Patients with CKD (N = 45,394) 
eGFR 30-59 mL/min/1.73m2 
(N = 43,410) 
eGFR <30 mL/min/1.73m2 
(N = 1,984) 
SSRI 
N = 17,124 
TCA 
N = 23,286 
Others 
N = 3,000 
SSRI 
N = 868 
TCA 
N = 976 
Others 
N = 140 
Depression, n (%)* 10,871 (63.5) 6,017 (25.8) 1,390 (46.3) 492 (56.7) 240 (24.6) 66 (47.1) 
Anxiety, n (%)* 5,904 (34.5) 4,874 (20.9) 897 (29.9) 227 (26.2) 181 (18.6) 38 (27.1) 
Neuropathic pain, n (%)* 942 (5.5) 3,348 (14.4) 201 (6.7) 55 (6.3) 143 (14.7) 8 (5.7) 
None of the above, n (%) 4,395 (25.7) 12,715 (54.6) 1,195 (39.8) 288 (33.2) 544 (55.7) 61 (43.6) 
CKD = chronic kidney disease, eGFR = estimated glomerular filtration rate, SSRI = selective serotonin reuptake inhibitor, 
TCA = tricyclic antidepressants. 
*Percentages are column percentages. Each patient may have one or more recorded diagnosis. 
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Table 5. Choice of antidepressants and initial prescription dose for patients with diagnosed depression.  
 Patients without CKD (N = 13,588) Patients with CKD (N = 19,076) 
 
without creatinine measurement 
 in CPRD  
N = 2,697 
with creatinine measurement 
 in CPRD 
N = 10,891 
with eGFR 30-59  
mL/min/1.73m
2 
at baseline 
N = 18,278 
with eGFR <30 
mL/min/1.73m
2 
at baseline 
N = 798 
 n (%)* 
Median initial dose 
(mg/day) [IQR] 
n (%)* 
Median initial dose 
(mg/day) [IQR] 
n (%)* 
Median initial dose 
(mg/day) [IQR] 
n (%)* 
Median initial dose 
(mg/day) [IQR] 
Selective serotonin 
reuptake inhibitors 
 
   
 
   
Citalopram 1,051 (39.0) 10 [10 – 20] 3,883 (35.7) 10 [10 – 20] 6,760 (37.0) 10 [10 – 20] 310 (38.9) 10 [10 – 20] 
Escitalopram 80 (3.0) 10 [5 – 10] 273 (2.5) 5 [5 – 10] 407 (2.2) 5 [5 – 10] 22 (2.8) 5 [5 – 10] 
Fluoxetine 381 (14.3) 20 [20 – 20] 1,270 (11.7) 20 [20 – 20] 2,171 (11.9) 20 [20 – 20] 99 (12.4) 20 [20 – 20] 
Fluvoxamine <5 (<0.2) n/a <5 (<0.1) n/a <5 (<0.1) n/a <5 (<0.6) n/a 
Paroxetine 35 (1.3) 20 [20 – 20] 97 (0.9) 20 [20 – 20] 133 (0.7) 20 [20 – 20] 11 (1.4) 20 [20 – 20] 
Sertraline 194 (7.2) 50 [50 – 50] 859 (7.9) 50 [50 – 50] 1,399 (7.7) 50 [50 – 50] 50 (6.3) 50 [50 – 50] 
Tricyclic and related 
antidepressants  
   
 
 
 
 
Amitriptyline 548 (20.3) 10 [10 – 15] 2,958 (27.2) 10 [10 – 20] 4,847 (26.5) 10 [10 – 15] 177 (22.2) 10 [10 – 15] 
Clomipramine <5 (<0.2) n/a 22 (0.2) 20 [10 – 37.5] 27 (0.2) 20 [10 – 37.5] <5 (<0.6) n/a 
Dosulepin 105 (3.9) 50 [25 – 75] 302 (2.8) 37.5 [25 – 75] 481 (2.6) 37.5 [25 – 50] 31 (3.9) 37.5 [25 – 75] 
Doxepin <5 (<0.2) n/a 17 (0.2) 25 [25 – 37.5] 23 (0.1) 25 [20 – 25] <5 (<0.6) n/a 
Imipramine <5 (<0.2) n/a 27 (0.3) 15 [10 – 25] 44 (0.2) 25 [10 – 30] <5 (<0.6) n/a 
Lofepramine 26 (1.0) 70 [70 – 140] 87 (0.8) 70 [70 – 140] 179 (1.0) 70 [70 – 140] 7 (0.9) 70 [70 – 140] 
Nortriptyline 10 (0.4) 15 [10 – 25] 84 (0.8) 15 [10 – 15] 155 (0.9) 10 [10 – 15] <5 (<0.6) n/a 
Page 55 of 67
http://mc.manuscriptcentral.com/pds
Pharmacoepidemiology and Drug Safety
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
Trimipramine <5 (<0.2) n/a 12 (0.1) 25 [15 – 37.5] 24 (0.1) 30 [15 – 50] <5 (<0.6) n/a 
Mianserin <5 (<0.2) n/a <5 (<0.1) n/a <5 (<0.1) n/a <5 (<0.6) n/a 
Trazodone 55 (2.0) 50 [50 – 100] 158 (1.5) 50 [50 – 100] 233 (1.3) 50 [50 – 75] 17 (2.1) 50 [50 – 75] 
Monoamine oxidase 
inhibitors** 
<5 (<0.2) n/a <5 (<0.1) n/a <5 (<0.1) n/a <5 (<0.6) n/a 
Other antidepressants:         
Agomelatine <5 (<0.2) n/a <5 (<0.1) n/a <5 (<0.1) n/a <5 (<0.6) n/a 
Duloxetine  15 (0.6) 60 [40 – 60] 83 (0.8) 40 [30 – 60] 164 (0.9) 40 [30 – 60] 5 (0.6) 60 [60 – 60] 
Flupentixol 17 (0.6) 1 [0.5 – 1] 46 (0.4) 0.5 [0.5 – 1] 82 (0.5) 1 [0.5 – 1] 6 (0.8) 0.5 [0.5 – 0.5] 
Mirtazapine 139 (5.2) 15 [15 – 15] 619 (5.7) 15 [15 – 15] 998 (5.5) 15 [15 – 15] 47 (5.9) 15 [15 – 15] 
Reboxetine <5 (<0.2) n/a <5 (<0.1) n/a <5 (<0.1) n/a <5 (<0.6) n/a 
Venlafaxine 19 (0.7) 75 [75 – 75] 66 (0.6) 75 [75 – 75] 94 (0.5) 75 [75 – 75] <5 (<0.6) n/a 
Two or more different 
antidepressants  
7 (0.3) n/a 20 (0.2) n/a 48 (0.3) n/a 5 (0.6) n/a 
CKD = chronic kidney disease, eGFR = estimated glomerular filtration rate, IQR = interquartile range. 
*Cell counts less than five have been suppressed to preserve patient privacy. 
**Phenelzine, isocarboxazid, tranylcypromine and moclobemide are combined due to small sample sizes. 
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